Spleen lymphoid tissue in white mice with an albumin model of experimental amyloidogenesis

Objective. Study the reaction of the white pulp of the spleen of laboratory mice in an experiment on parenteral administration of human pharmacy albumin.

Materials and methods. Nine 30-day-old mice were divided into three groups of three mice each (intact and two experimental). Experimental mice were intraperitoneally injected with a human albumin pharmacy drug at a dose of 0.9 ml every other day for 30 days. The animals of the intact and first experimental groups were removed from the experiment by decapitation on the 30th day from the beginning of the experiment, the second experimental group – 1 month after the last injection (60 days from the beginning of the experiment).

Results. Albumin increased the wet mass of the spleen from 0.74±0.01 g (control) to 1.40±0.02 and 1.20±0.04 g in groups 1 and 2, respectively; induced amyloidosis, determined by the relative area of the congophilic substance in 4 microns of paraffin sections of the spleen – 13.32±1.31 and 23.47±0.84% in groups 1 and 2, respectively; reduced the average area of lymphoid nodules from 1.34±0.10•10⁵ mkm² (control) to 1.18±0.08•10⁵ and 0.91±0.04•10⁵ mkm² in groups 1 and 2, respectively; increased the relative area of white pulp – from 22.65±2.30% (control) to 34.99±2.34 and 31.87±1.68% in groups 1 and 2, respectively, and reduced the relative area of the red pulp – from 77.35±4.20% (control) to 65.01±2.34 and 68.13±1.68% in groups 1 and 2, respectively, which led to a significant decrease in the index (red pulp) / (white pulp) from 6.67±1.39 (control) to 2.79±0.42 and 2.65±0.29 in groups 1 and 2, respectively. In all cases, the differences are statistically significant.

Conclusions. Parenteral administration of human albumin to mice at a dose of 0.9 ml of a pharmacy drug causes amyloid damage to the spleen. Discontinuation of the introduction of amyloidogen protein does not prevent the development of the amyloid process that has begun.